Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)

 

Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Assassi S et al.


 

Acceder

Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial

Kuwana M et al.

 

Acceder

Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial

Highland KB et al.
 

Acceder

 

 

Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial

Humphries S et al.

 

Acceder

Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON

Allanore Y et al.

 

Acceder

Drug-Drug Interaction Study of Nintedanib (Ofev) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Vonk MC et al.
 

Acceder